Brainstorm backs off a controversial plan to sell its experimental ALS med, but this issue is far from over
Brainstorm Cell Therapeutics $BCLI won’t be angling to make any profits off the new ‘Right to Try’ bill after all.
After stirring or hornet’s nest of angry Twitter memes after Bloomberg quoted CEO Chaim Lebovits saying that they were preparing to sell their drug to desperate ALS patients, including one who lent his name to the legislation, the micro-cap biotech this morning is backing off the idea.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters